Terumo's upgrade is a tax rebate dressed as a growth story

THERUMU, one of Japan's largest medical-device makers, has lifted its profit outlook for the fiscal year ending March 2027. The headline is cheerful. The detail is less so. The upgrade is driven partly by two items that have nothing to do with the company's underlying business: a refund of U.S. tariffs and proceeds from a legal settlement. One is money the American government previously collected without legal authority. The other is the resolution of a dispute. Neither reflects pricing power, market share, or product innovation.

The timing of the refund windfall is worth a brief explanation. In February 2026, the Supreme Court ruled in Learning Resources, Inc. v. Trump that the International Emergency Economic Powers Act — the legal authority the executive had relied upon — did not permit the imposition of tariffs. That decision invalidated a broad sweep of levies introduced from early 2025 on goods from China, Canada, Mexico and other countries. Customs and Border Protection (CBP) subsequently began processing refunds. By late July, more than $104 billion in claims had been accepted for processing and approximately $71 billion had been finalised, according to testimony before the Court of International Trade. The total refund liability is estimated at roughly $166 billion. In June alone the United States paid out about $49 billion in refunds, nearly double the $23.6 billion it collected that month in tariff revenue.

Terumo is one of the importers receiving a cut. The company's first-quarter results for the fiscal year ending March 2027, published on August 7th, showed improved results with annual profit guidance raised on the back of these U.S. tariff refunds and settlement proceeds. The company also raised its full-year dividend to ¥36 per share, up from ¥30 in the prior year. The exact breakdown of the one-off items is not separately disclosed in the available reporting, which is itself a point of friction: investors cannot easily separate what the business earned from what the government returned.

That separation is the whole point. The tariff refund is a government accounting correction, not a business-line recovery. A settlement gain is a legal resolution, not a competitive advantage. Both improve the headline for the quarter in which they book, and both vanish from the income statement once they have been recognised. An investor who extrapolates from a quarter swollen by such items will end up paying for earnings that will not recur.

The underlying business, by contrast, is quite strong. In the fiscal year ended March 2026, revenue rose 9.2% to ¥1.13 trillion and adjusted operating profit grew 11.8% to ¥219.4 billion. Overseas revenue expanded by 11%, driven by the interventional systems division, where access devices and cardiovascular products — including the rapidly growing TAVI (transcatheter aortic-valve implantation) market — have been the bright spots. In the first quarter of FY2026, the cardiovascular segment posted 70% revenue growth on a local-currency basis, lifted by the U.S. market. Operating profit for that quarter was ¥55.9 billion. These are the numbers that should carry the investment case, not the refund cheque.

Terumo's initial full-year guidance for FY2027 projected revenue of ¥1.239 trillion, an increase of 9.5%, implying that the organic growth trajectory is already intact without the one-offs. Profit attributable to owners was guided to grow by 21.6%. The question the upgraded outlook raises is not whether the company is doing well. It is how much of the improvement is permanent and how much is a fiscal mirage.

There is a further complication. The tariff refunds are not the end of the trade story. They are merely the first act. While the IEEPA tariffs have been unwound, the administration has pivoted to Section 301 of the Trade Act of 1974, a statute that the Supreme Court did not touch. In July 2026, the Office of the U.S. Trade Representative announced final action in Section 301 investigations covering 60 economies, citing failures to enforce prohibitions on forced-labour imports. Those new tariffs, combined with existing Section 338 levies, are pushing the average U.S. import tariff back above the IEEPA-era level to 12.4%, up from a May low of 7.7%, says Allianz, a European insurer and research house. The medical-device industry is particularly exposed: an estimated 62% of devices used in the United States are imported, and nearly 70% of U.S.-marketed devices are manufactured abroad.

Terumo, as a foreign medical-device company with significant U.S. operations and supply chains, faces the same trade-inflation risk that its competitors do. The IEEPA refund was a reprieve. The Section 301 programme is a fresh levy, one with a statutory basis that is less vulnerable to judicial reversal. If anything, the tariff refund makes the next cycle more perilous: it creates the illusion that import costs can be reversed by litigation, while the administration builds a more durable wall of Section 301 tariffs around the same goods.

The broader lesson is one that investors should apply to any company riding a tariff-refund headline. Government mistakes can produce corporate windfalls, but they do not produce durable earnings power. The incentive for a firm to build a business model around the hope of the next judicial reversal is exactly the kind of rent-seeking that free-trade policy was supposed to prevent. Terumo is not doing anything wrong. It is simply collecting what is owed to it. The temptation lies on the other side of the screen: in the investor who confuses a one-off credit with a trend.

The real thesis for Terumo remains the one it was building long before the Supreme Court ruled. It is a company with growing exposure to high-value cardiovascular procedures, a strong position in interventional access devices, and a track record of margin expansion. Those are the fundamentals that matter. The tariff refund is a footnote. The dividend raise to ¥36 is a signal of confidence in the underlying flow. The settlement gain is a line item that will not repeat.

Better to price the business, not the rebate.